AUM BIOSCIENCES presented at the 2nd Annual Accelerating Clinical Trials in Asia Conference, Singapore, 18th – 21st September 2018.
Dr. Harish Dave, AUM Biosciences’ Co-Founder and Chief Medical Officer presented at the 2nd Annual Accelerating Clinical Trials Asia Conference on Moving Beyond Oncology: A small molecular strategy. The Conference was part of PHARMACON Asia.
AUM Biosciences is an oncology-focused biotechnology company that aims to accelerate the development of innovative, affordable cancer medicines for patients in Asia and around the world. AUM Biosciences focuses on early-stage development of innovative medicines for the treatment of Asian-prevalent cancers.
AUM Biosciences will have a specific focus on indications such as hepatocellular carcinoma, head and neck cancer, gastric cancer, cholangiocarcinoma, triple negative breast cancer, prostate and colorectal cancer. With a huge opportunity to identify targets for unmet medical needs, AUM Biosciences will partner and collaborate with leading research institutes, clinicians and pharmaceutical companies bringing new, affordable and effective therapies to patients in need.